Presentation Title: Appropriate crosslinking is required for co-stimulatory activity of human CD27 antibody in a transgenic mouse model
Presentation Time: Tuesday, Apr 03, 2012, 8:00 AM -12:00 PM
Location: McCormick Place West (Hall F), Poster Section 19
Poster Section: 19
Poster Board Number: 21
Author Block: Li-Zhen He1, Naseem Prostak1, Andrea Crocker1, Jeffery Weidlick1, Jenifer Widger1, Crystal Sisson1, Laura Vitale1, Martin J. Glennie2, Tibor Keler1. 1Celldex Therapeutics, Inc., Phillipsburg, NJ; 2Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton General Hospital Southampton, Southampton, United Kingdom
Abstract Body: CD27 is a member of TNFR superfamily. It constitutively expresses on the majority of T cell and a subset of NK cells, playing key roles in T cell activation and survival and in NK cell proliferation and cytotoxicity upon interaction with ligand CD70. Some antibodies to mouse CD27 have been reported that display agonistic and anti-tumor activities while other mAbs had less anti-tumor activity and were depleting. We hypothesized that differences in these antibodies may be due to Fc receptor engagement, as has recently been shown for the adjuvant and anti-tumor activities of agonistic mouse CD40 mAbs, which is also member of TNFR superfamily. We have developed and previously described a human anti-human CD27 antibody (1F5) and a human CD27 transgenic mouse model (hCD27-Tg) to explore the therapeutic potential of targeting CD27. In this study, we examined the effect of modifying the constant regions of the 1F5 mAb on its ability to enhance antigen specific T cell responses. With the original 1F5 hIgG1 as template, a panel of 1F5 variants was made including 1F5 mIgG1, 1F5 mIgG2a, 1F5 mIgG1D265A and 1F5 hIgG1N297S using molecular cloning techniques. All of the variants retained equal binding to hCD27 as shown by ELISA and flow cytometry studies. In addition, Biacore analysis confirmed the expected pattern of binding to human and mouse FcγRs. Co-injection of 1F5 or its variants with ovalbumin enhanced antigen-specific CD8 T cell response to different extents, as detected by SIINFEKL-specific IFNγ-ELISPOT and ICS. The 1F5 mIgG1 induced the highest number of IFNγ-producing CD8+ cells, whereas 1F5 mIgG2a was very weak at enhancing the CD8 T cell response. The hIgG1 version of 1F5 was intermediate in activity. Introduction of the D265A mutation that disrupts FcγRs binding into the mIgG1 eliminated the co-stimulatory function of 1F5. Similarly, the 1F5 hIgG1N297S also showed reduced activity compared to the original 1F5 hIgG1. The isotype-specific effects on our anti-hCD27 mAb are surprisingly consistent with the findings described for the agonistic anti-mCD40 mAbs, and imply that engagement of the inhibitory Fcγ receptors (FcγRIIb) is driving the co-stimulatory activity in this model. Interestingly, the 1F5 hIgG1 triggered a significant T cell response, despite the lack of FcγRIIb binding by Biacore analysis. The effect of these variants on anti-tumor activity in hCD27 transgenic mice is currently being investigated. The 1F5 hIgG1 mAb (CDX-1127) is currently undergoing clinical evaluation in a phase 1 trial of patients with advanced cancers.
thanx chiragg...Im jealous...when I was in pharma I went to all the big conventions, stayed in great Hotels, ate delicious foods and drink, retirement is Nice but I do miss the perks of work!
enjoy..take copious notes!
cdx-1127 is being tested on a multitude of cancers.
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
This study is currently recruiting participants.
Verified December 2011 by Celldex Therapeutics
First Received on October 12, 2011. Last Updated on December 2, 2011 History of Changes
Sponsor: Celldex Therapeutics
Information provided by (Responsible Party): Celldex Therapeutics
ClinicalTrials.gov Identifier: NCT01460134
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.
Condition Intervention Phase
CD27 Expressing B-cell Malignancies
CD27 Expressing Solid Tumors
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Primary Lymphoma of the Central Nervous System
Marginal Zone B Cell Lymphoma
Renal (Clear) Cell Carcinoma
Hormone-refractory Prostate Adenocarcinoma
Non-small Cell Lung Cancer